B. Riley raised the firm’s price target on Zymeworks (ZYME) to $40 from $30 and keeps a Buy rating on the shares. Zymeworks’ shift to a royalty-aggregation strategy aims to optimize future de-risked ...

APT24 and Autumn Dragon launch multi-year espionage campaigns using BADAUDIO, supply chain attacks, and new CVE-2025-8088 ...

Corporate representation at COP30 has sharply declined since the 2021 Glasgow summit, replacing high-profile marketing stunts ...

Utah's Minor Protection in Social Media Act requires social media platforms to take extra care with minor users. But a ...

Nicholas Crypto Income ETF offers a unique blend of cryptocurrency, crypto miners, trading platforms, and semiconductor ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Vanda advances with strong Fanapt growth, late-stage catalysts, GLP-1 potential, higher investment and solid balance sheet ...

Modern LLMs typically return answers through a token-by-token streaming process, where each token is packaged into a separate ...

Key Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, China ...

Trust us, we get how challenging those conversations can be. That’s why our experts put together a guide to help you navigate ...

See how models, tools and evals fit together in Agentic AI, plus tips on pitfalls, deployment gaps, and where no code options ...